renal cell carcinoma
With Positive Multi-Site Trial Data, Elypta Poised for Launch of Kidney Cancer Surveillance Test
Premium
The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.
New Data in Kidney Cancer Bolsters Promise of Mass Spec Technique for Assessing Surgical Margins
Premium
Investigators hope they can establish the technology in kidney cancer and other tumor types to improve surgery success and associated survival outcomes.
Myriad Genetics, MD Anderson Partner to Study MRD Testing in Renal Cell Carcinoma
Researchers will explore whether Myriad's Precise MRD test can be used to inform treatment, monitor disease progression, and track treatment response.
Metabolism-Based Liquid Biopsy Tool Being Developed by Elypta for Recurrent Renal Cell Cancer
Premium
Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.
Liquid Biopsy Platform Developer Elypta Receives €2.35M in EU Funding
The firm said that it will use the Horizon 2020 Phase II grant to fund a multicenter trial aimed at validating its platform for early detection of recurrent renal cell carcinoma.